In vitro and in vivo antifungal activities of 6-[(N-4-bromophenyl) amino]-7-chloro-5,8-quinolinediones

Archives of Pharmacal Research

Volumn 20, Issue 6, 1997, Pages 586-589

  Ryu, Chung Kyu ^a   Kim, Dong Hyun ^b   Kwon, Sang Mee ^a   Jung, Sung Hee ^a   Kim, Sung Hee ^a  

^a Ewha Womans University   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

6 (N 4 Bromophenyl)amino 7 chloro 5,8 quinolinedione; Candida albicans; Candidiasis; In vivo antifungal activity; Minimum inhibitory concentration

Indexed keywords

EID: 19444382504     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02975216     Document Type: Article

References (14)

1. Clark, A. C., The need for new antifungal drugs, in Fernandes, P.B.(Eds.). New Approaches for Antifungal Drugs. Birkhaeser, Boston, pp. 1-19, 1992.
2. Fisher, M. A., Lee, P. G. and Tarry W . F., Fluconazole treatment of candidiasis in normal and diabetic rats. Antimicrob. Agents Chemother., 33, 1042-1045 (1989).
3. Georgopapadakou, N. H. and Walsh. J., Human mycoses: Drugs and targets for emerging pathogens. Science, 264, 371-373 (1994).
4. Hudson, A. T., Atovaquone-A novel agent for the treatment of malaria, PCP and toxoplasmosis. in Bentley, P. H. and Ponsford, R. (Eds.). Recent Advances in the Chemistry of Anti-infective Agents. Royal Society of Chemistry, Cambridge, pp. 322-335, 1992.
5. Jeschke, P., Linder, W., Mueller, N. and Dehne, H. W., Fungicides based on amino-substituted quinoline-quinones. Ger. Offen., DE 4,208,874 (1993).
6. Mcginnis M. R. and Rindali, M. G., Antifungal drug. in Lorian, V.(Eds.), Antibiotics in Laboratory Medicine, 3rd ed., Williams and Wilkins, Baltimore, pp. 198-256, 1991.
7. Park, Y. M., Kim, H. J, Kim, D. H., Lee. I. K. and Ryu, C. K., The evaluation of in vivo antifungal activities of 6-[(N-4-fluorophenyl)amino]-7-chloro-5,8-quinolinediones. Yakhak Hoeji, 40, 4-9 (1996).
8. Roberts, H., Choo, W. M., Smith, S. C., Marzuki, S., Linnane, A. W., Porter, T.H. and Folkers, K., The site of inhibition of mitochondrial electron transfer by coenzyme Q analogs. Arch. Biochem. Biophys., 191, 306-315 (1978).
9. Ryu, C. K., Kim, D. H. Yun, Y. P., Heo, M. Y., Lee, B. M., Jang, S. J., Kim, H. J. and Park, Y. M., The evaluation of in vivo antifungal activities and toxicities of 6-[(N-4-chlorophenyl)amino]-7-chloro-5,8-quinolinediones. Yakhak Hoeji, 39, 417-426 (1995).
10. Ryu, C. K. and Kim, D. H., The antifungal susceptibility tests of 5,8-quinolinediones against Candida species. Arch. Pharm. Res., 17, 483-486 (1994a).
11. Ryu, C. K. and Kim, H. J., The synthesis of 6-(N-arylamino)-7-chloro-5,8-quinolinedione derivatives for evaluation of antifungal activities. Arch. Pharm. Res., 17, 139-144 (1994b).
12. Sternberg, S., The emerging fungal threat. Science, 266, 1632-1634 (1994).
13. Sugar A. M., Salibian, M. and Goldani, L. Z., Saperconazole therapy of murine disseminated candidiasis: Efficacy and interaction with amphotericin B. Antimicrob. Agents Chemother., 38, 371-373 (1994).
14. Viscoli, C. and Terragna, A., Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob. Agents Chemother., 35, 365-367 (1991).